Clinical trials: Circulating Tumor DNA (ctDNA)
Neoplasms, Cancer
The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types
GRAIL is using high-intensity sequencing of circulating cell-free nucleic acids (cfNAs) to develop blood tests to detect cancer early.
- Trial name
- NCT03085888
- Where
- 35 sites in United States
- Volunteers
- 99,481 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Cancer, Lung, Cancer, Breast
Early Detection of Five Common Cancers Using the ctDNA Analysing Test
This is a multi-centre, prospective cohort study, aiming to evaluate a blood test in early detection of the four common cancers, based on the investigation of the circulating tumour DNA (ctDNA).
- Conditions
- Cancer, Lung, Cancer, Breast, Cancer Liver, Cancer, Colorectal
- Trial name
- K-DETEK (NCT05227261)
- Where
- Vietnam
- Volunteers
- 9,057 people, healthy volunteers welcome
- Sponsor
- Gene Solutions
Lung Nodule
Non-Invasive ctDNA Methylation Detection for Lung Nodule Patients
Low-dose computed tomography (LDCT) is recommended for early-stage lung cancer screening. However, it is often difficult to determine indolent lesions from more aggressive tumors without an invasive intervention or prolonged…
- Trial name
- NCT03685669
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Shanghai Chest Hospital
Cancer
Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial
The Galleri test is a new test that looks for potential signs of cancer in a blood sample. The test can find many different types of cancer but cannot find all cancers.
- Trial name
- NHS-Galleri (NCT05611632)
- Testing
- Multi-cancer early detection test (Galleri test)
- Where
- United Kingdom
- Volunteers
- 142,318 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Colon Cancer, Colon Adenomas
Plasma ctDNA in Patients Undergoing Diagnostic Colonoscopy
When the DNA inside of human cells undergoes certain alterations (mutations), the cells may develop into a cancer. The cancer cells may shed this DNA into the blood stream.
- Conditions
- Colon Cancer, Colon Adenomas, Colon Polyps
- Trial name
- NCT02665299
- Where
- United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Pathway Genomics
Colorectal Cancer, Adenoma
The Implication of Plasma ctDNA Methylation Haplotypes in Detecting Colorectal Cancer and Adenomas
This is a multicenter, clinical study. This study is to evaluate the sensitivity of plasma ctDNA methylation haplotypes in detecting colorectal cancer, adenoma and the specificity in healthy individuals.
- Trial name
- NCT03737591
- Testing
- Next-generation sequencing (NGS)
- Where
- China
- Volunteers
- 1,138 people, healthy volunteers welcome
- Sponsor
- Fudan University
Cancer
Galleri® in the Medicare Population.
This multi-center comparative prospective cohort study is designed to assess the real world clinical impact, including safety and test performance, of Galleri®, a blood-based multi-cancer early detection (MCED) test.
- Trial name
- NCT05673018
- Testing
- Multi-Cancer Early Detection Test (Galleri®)
- Where
- 72 sites in United States
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Lung Cancer, Colorectal Cancer
ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population
This is a prospective, multi-centre interventional study evaluating the feasibility of blood-based multi-cancer early detection test in asymptomatic screening cohort.
- Conditions
- Lung Cancer, Colorectal Cancer, Liver Cancer, Grastic Cancer
- Trial name
- NCT06790355
- Testing
- multi-cancer early detection
- Where
- 4 sites in China
- Volunteers
- 2,527 people, healthy volunteers welcome
- Sponsor
- Shanghai Weihe Medical Laboratory Co., Ltd.
Neoplasms, Cancer
The Circulating Cell-free Genome Atlas Study
GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood.
- Trial name
- CCGA (NCT02889978)
- Where
- 140 sites in United States, Canada
- Volunteers
- 15,254 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.
Colorectal Cancer, Colorectal Adenoma
Circulating Tumor DNA in Patients Summoned for Colonoscopy; - a Liquid Biopsy for Detection, Characterization, Individualized Treatment and Follow-up of Colorectal Cancer
CoLiQ is a clinical study designed to evaluate the clinical usefulness of circulating tumor DNA (ctDNA) markers found in blood, as a liquid biopsy for diagnosis, prognosis and follow-up of colorectal cancer.
- Trial name
- CoLiQ (NCT06307938)
- Testing
- liquid biopsy
- Where
- Norway
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Helse Nord-Trøndelag HF
Multiple Myeloma
ctDNA Methylation Sequencing for Myeloma
1. To carry out research on minimal residual disease (MRD) monitoring in patients with multiple myeloma (MM) based on plasma circulating tumor DNA (ctDNA) methylation sequencing, which aims to explore new MRD detection methods…
- Trial name
- NCT05578625
- Testing
- plasma circulation DNA methylation sequencing
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Non Small Cell Lung Cancer
Blood Testing to Detect Cancer Recurrence in Patients With Early-Stage Non-Small Cell Lung Cancer
This observational study will evaluate whether a blood test can detect the return of non-small cell lung cancer at least three months before it is identified on routine imaging.
- Trial name
- NCT07854769
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Colorectal Cancer, Pancreatic Adenocarcinoma
Circulating Tumor DNA Exposure in Peripheral Blood
This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the…
- Conditions
- Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT03517332
- Where
- 6 sites in United States, Switzerland
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Quantgene Inc.
Healthy Volunteer, Prostate Cancer
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes.
- Conditions
- Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer
- Trial name
- NCT04354064
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Carcinoma, Non-Small-Cell Lung
Comparison of Circulating Tumor DNA and Tumor Tissue DNA by Targeted Sequencing in Non-Small Cell Lung Cancer
Conduct a prospective study to compare gene detection by ctDNA with tumor tissue DNA via targeted DNA sequencing in surgical NSCLC patients.
- Trial name
- NCT02645318
- Where
- China
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Colorectal Cancer (CRC) Screening
Smartphone-enabled Hybrid Identification of Early CoLorectal Disease Using Blood-Based Cancer Testing Across TeXas
The goal of this prospective implementation study is to understand the impact of a blood-based screening test (BBST) for colorectal cancer (CRC) on patient acceptability of and adherence to CRC screening as well as the rate of…
- Trial name
- SHIELD-TX (NCT07398456)
- Testing
- Educational Information via Smartphone App
- Where
- United States
- Volunteers
- 5,500 people, healthy volunteers welcome
- Sponsor
- Baylor Research Institute
Ovarian Neoplasms
Liquid Biopsies for Improving the Pre-operative Diagnosis of Ovarian Cancer
An accurate preoperative diagnosis of an ovarian tumor is important for the patients' surgical work-up, proper referral to oncological centers and for the patients' mental wellbeing since uncertainty about the nature (benign vs…
- Trial name
- OVI-DETECT (NCT04971421)
- Testing
- ctDNA - circulating tumor DNA, TEP - Tumor Educated Platelets
- Where
- 4 sites in Netherlands
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer, Lymph Node Metastasis
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
The purpose of this study is to determine how circulating tumor DNA (ctDNA), a sign of minimal residual disease (MRD), is detectable after surgery in patients with early HR+/HER2- breast cancer that has spread to 1-3 lymph nodes.
- Trial name
- NCT07025785
- Testing
- Circulating tumor DNA
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Primary Central Nervous System Lymphoma (PCNSL)
Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China
This project aims to establish and prospectively register a longitudinal, multimodal biobank for primary central nervous system lymphoma (PCNSL).
- Trial name
- CLIMB (NCT07842835)
- Testing
- High-dose methotrexate-based therapy, Bruton tyrosine kinase inhibitor-based therapy
- Where
- 3 sites in China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Xiaohui Ren
Early Detection of Cancer, Cancer
REFLECTION: A Clinical Practice Learning Program for Galleri®
REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 14,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in…
- Trial name
- NCT05205967
- Testing
- MCED, SOC
- Where
- 16 sites in United States
- Volunteers
- 14,633 people, healthy volunteers welcome
- Sponsor
- GRAIL, Inc.